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Cortisone effects on growth, food efficiency, and in vitro growth
hormone release. These studies were designed to investigate the cause
of growth retardation during glucocorticoid treatment in rats. In young
animals, body weights and amounts of food consumed were measured
at two-day intervals, beginning at 29 days of age. Average food intake
and food efficiency were calculated. Animals were treated with corti-
sone (CORT, 5 mg/rat/day, s.c.) or saline (SAL) for eight days between
37 and 44 days. Growth hormone (Gil) release by dispersed pituitary
cells in response to nine concentrations of Gil-releasing hormone
(GHRH) were tested by in vitro perifusion at 45 and 73 days. As
previously shown, CORT caused a cessation of growth during the
treatment period, and body weight failed to catch up. Food efficiency
was decreased during CORT treatment. All parameters of in vitro Gil
release including basal GH secretory rate, overall GH response to
GHRil, and the GHRH concentration-response curves were signifi-
cantly increased by CORT in the 45-day-old animals. An age-related
increase in GH release was also observed between the 45 and 73 day
saline-treated animals. These results support the hypothesis that gluco-
corticoids inhibit growth by induction of changes in food metabolism
and Gil secretion. The effect on the pituitary gland itself paradoxically
involves an increase in GH secretory capacity in response to GHRH.
vitro culture methods have shown that glucocorticoids enhance
GH secretion from pituitary cells [14—16].
To further clarify the influence of glucocorticoids, the present
study was designed to investigate the effects of prepubertal
cortisone treatment on growth, food intake and efficiency, and
in vitro GH release by dispersed pituitary cells using an in vitro
perifusion technique.
Methods
Animals
Male Long-Evans rats were obtained at 25 days of age
(Charles River Laboratories, Wilmington, Massachusetts,
USA), and maintained in an environmentally controlled animal
facility (12 hours of light, 12 hours of darkness), with the
temperature between 21 and 23°C. Animals were fed standard
rodent laboratory chow (Purina, St Louis, Missouri, USA) in a
powdered form. Both food and water were available ad libitum.
Experimental design
Glucocorticoid therapy is a common treatment for nephrotic
syndrome [1, 2] and bronchial asthma [3] in children. One of the
complications of glucocorticoid administration, however, is the
growth failure that has been observed in both humans [4, 5] and
laboratory animals [6]. Although the mechanism of this growth
failure has not been fully investigated, glucocorticoid effects on
the growth hormone (GH) system appear to play a significant
role. The details of the GH effects have not been established,
and may be at the level of the central nervous system, pituitary,
or peripheral target tissues. With regard to peripheral effects,
there has been recent evidence to suggest that glucocorticoids
reduce the synthesis of insulin-like growth factor-I (IGF-I) [7].
In vivo studies have also shown that both glucocorticoid
administration and endogenous hypercortisolism decrease GH
secretion in response to various stimuli [8—12]. Recent evidence
suggests that this in vivo inhibition of GH secretion may be
mediated by somatostatin secretion from the hypothalamus
[13]. In contrast to the in vivo results, experiments using in
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Animals were weighed at two-day intervals. Food intake was
also quantitated every other day as the weight-difference be-
tween food containers when full and just before refill. Average
food intake was expressed as grams of food consumed per 100
grams of mean body weight per day. Food efficiency was
calculated as the percentage of weight gained (in grams) relative
to food intake. Both food intake and food efficiency were finally
expressed as overall mean values for the periods: "Before"
treatment—29 to 37 days of age (29 to 37d); "During" treat-
ment—37 to 45d, and "After" treatment: "l"—45 to 54d,
"2"—54 to 62d, and "3"—62 to 70d.
Treatment with cortisone was begun at 37 days of age.
Cortisone-acetate (CORTONE, Merck, Sharp & Dohme, West-
point, Pennsylvania, USA) was suspended in physiological
saline at a concentration of 50 mg/ml. Each animal received
either cortisone (CORT) at a dose of 5.0 mg/day or saline (SAL)
by subcutaneous injection. The treatment was continued for a
period of eight days. Two cortisone and two saline groups were
used. One group of each treatment was maintained for 28 days
after cessation of treatment (73 days of age, 73d), and another
was used immediately upon completion of treatment (45 days of
age, 45d). In this regard, four groups of animals were studied
simultaneously: 45d-CORT, 45d-SAL, 73d-CORT, and 73d-
SAL.
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Perifusion of dispersed pituitary cells
The release of GH in response to Gil-releasing hormone
(GHRH) by pituitary cells from the four groups of animals was
documented using a perifusion system previously described by
Evans, Cronin and Thorner [17]. Three rats provided pituitary
tissue for each experimental group, and four repetitions of the
experiments were performed on separate days using a total of
48 rats. On each experimental day, pituitary glands were
collected after rapid decapitation under anesthesia. The poste-
rior pituitary (neurohypophysis) was dissected free, and the
anterior pituitary (adenohypophysis) was diced in Minimal
Essential Medium (SMEM, Gibco, Grand Island, New York,
USA). The fragments were transferred to 10 ml of SMEM
containing 0.25% (wt/vol) trypsin (Worthington Biochemical
Corp, Freehold, New Jersey, USA) and placed in Bellco
spinner flasks (Belico Glass Co, Vineland, New Jersey, USA)
which had been silicon-coated (Sigmacote, Sigma Chemical Co,
St Louis, Missouri, USA) to prevent the fragments and cells
from sticking to the glass. The atmosphere of the flasks was
95% oxygen and 5% carbon dioxide. Incubation and stirring
were maintained for one hour, after which the fragments were
collected by centrifugation and transferred to SMEM contain-
ing 1% BSA (bovine serum albumin, Sigma) to neutralize the
trypsin. Cells were dispersed by gentle trituration using a 1.0 ml
pipetter (Pipetman, Rainin Instrument Co, Woburn, Massachu-
setts, USA). An aliquot of cells was taken for determination of
the numbers of cells by the trypan blue dye exclusion test using
a standard hemocytometer. The cells were gently mixed with
BioGel P2 (200 to 400 mesh, Bio-Rad Laboratories, Richmond,
California, USA) which had been preswollen overnight in
normal saline. The pituitary cell-BioGel mixture was packed
into 2.0 ml plastic syringes (Sabre International Products Ltd,
Reading, Berkshire, England, UK), which served as the pen-
fusion chambers. Cells were maintained at 37°C by submersion
of the chambers in a water bath. Perifusion was performed with
penistaltic pumps (Buehler Instruments, Fort Lee, New Jersey,
USA) using Medium 199 (Gibco) containing 0.25% BSA, 10
U/mI penicillin, 0.5 g/ml streptomycin, 187.5 ng/ml amphoter-
icin-B, and 5 sg/ml gentamicin. The mean flow rate (approxi-
mately 0.43 mI/mm) was specifically quantitated for each pen-
fusion column. Pituitary cells were allowed to equilibrate to
perifusion conditions for four hours, at which time GHRFI was
administered as 2.5-minute pulses at 30-minute intervals. The
concentrations of GHRH (0.01, 0.03, 0.1, 0.3, 1,0, 3.0, 10, 30,
and 100 nM) were applied in a random order. Eluate was
collected as five-minute fractions and stored at —20°C until
measurement of Gil by radioimmunoassay (RIA).
RIA
Concentrations of Gil were measured using RIA reagents
provided by Dr. A.F. Parlow and the National Pituitary Hor-
mone Program of the NIDDK. Anti-rat Gil serum (S-4) and rat
GH reference preparation RP-2 were used. The assay standards
were set up in triplicate. Intrasssay coefficients of variation
were 5.8% and 6.7% at 0.5 and 1.0 ng/tube, respectively, and
the interassay coefficient of variation was 8.3% at 0.575 ng/tube.
Data analysis
GH secretion was measured with specific reference to the
number of pituitary cells and the flow rate of each perifusion
column. In this respect, GH secretion was expressed as Secre-
tory Rate (SR) in ng!min/10 million cells. Secretory rate was
calculated by the formula SR = 10(FR)/C, where FR = flowrate
(ml/min) and C = number of cells (millions). The Gil secretion
in response to a given GHRH concentration was calculated as
the mean secretory rate above baseline during the 30-minute
period immediately following administration, as described pre-
viously [18]. Concentration-response curves were determined
for each treatment group, and the relationship between Gil
secretory rate and the log of the GHRH concentration was
appraised by regression analysis using orthogonal polynomials
to test separately for linear, quadratic, cubic, fourth, fifth, sixth
and seventh order response characteristics. All other statistical
comparisons among group means were accomplished using
analysis of variance with Duncan's multiple range test. Statis-
tical significance was accepted at P < 0.05.
Results
Weight gain
Changes in body weight are shown in Figure 1. A CORT-
induced inhibition of the normal increase in body weight
became apparent within four days of treatment (day 41, P <
0,05 vs. SAL control). During CORT treatment there was no
significant increase in body weight. After cessation of CORT,
animals showed increases in body weight beginning at day 51 (P
< 0.05), and continuing until the end of the experiment. As
shown in the figure, however, body weights were significantly
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Fig. 1. Effects of cortisone (• •) or saline (O----O) treatment on
growth. During cortisone treatment there was no significant increase in
body weight. Upon cessation of cortisone, animals showed increases in
body weight beginning at day 51 (P < 0.05), but weighed less than
saline-treated controls at all post-treatment time intervals.
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Fig. 2. Changes in food intake in cortisone () and saline (LI) treated
animals. Food intake was measured every other day. Overall mean
values were calculated for the periods "Before", "During", and "After
1, 2, and 3" for the appropriate days of age, as shown. A gradual,
age-related decrease in food intake is shown. Except for the period
during treatment, the decline was linear for both groups (P < 0.0001).
Food intake in cortisone-treated animals was not different from saline
control during treatment, but was greater than controls at all time
intervals after treatment (as identified by asterisks, P < 0.05). The latter
effect was due to the lower body weights after cortisone treatment.
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Fig. 3. Changes in food efficiency for cortisone () and saline (LI)
treated animals. Food efficiency is expressed as a percentage (%) of
weight gained per unit of food intake. Overall mean values were
calculated for the appropriate periods, as described for Figure 2. The
saline group showed an age-related, linear decline in food efficiency
through all time intervals, including the injection period (P < 0.0001).
The cortisone treated animals showed a linear decline with specific
reference to the period before and after cortisone treatment (P =
0.0148). During cortisone treatment, food efficiency was significantly
lower than that for any other time interval except the last (as identified
by asterisks: P < 0.005 vs "Before", P < 0.005 vs. "After 1", P <
0.025 vs. "After 2"). The value for cortisone-treated animals was also
significantly lower than that for saline controls during treatment (as
identified by the star: P < 0.0005). There was no difference in food
efficiency between the two groups at any other time.
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less than the SAL control group at every time interval after
CORT treatment.
Food intake and efficiency
Changes in food intake, as a function of grams consumed per
100 grams mean body weight per day, are shown in Figure 2. A
gradual age-related decline was observed with specific regard to
the periods before and after CORT or SAL treatment. The
decline followed a linear pattern for the CORT and SAL groups
(P < 0.0001 for both). The CORT-treated group showed a
significantly greater intake than the SAL controls at all time
intervals after treatment (P < 0.05). The latter effect was due to
the lower body weight of the CORT-treated animals, rather than
to any difference in the amount of food eaten.
The linear decline in food intake was interrupted by both
CORT and SAL treatment, during which the values were lower
than before treatment (P < 0.005 for both CORT- and SAL-
treated), but not different from the first period after treatment.
Values for the CORT and SAL groups were not different from
each other during the treatment period.
Food efficiency data are illustrated in Figure 3. The SAL
control group showed an age-related linear decline during all
time intervals, including the injection period (P < 0.0001). The
CORT-treated animals showed a linear decline in food effi-
ciency with specific reference to the periods before and after
CORT treatment (P = 0.0148). Administration of CORT re-
sulted in an interruption in the linear progression of food
efficiency during the treatment period. This value was signifi-
cantly lower than that for all other time periods except the last
(P < 0.005 vs. "Before": P < 0.005 vs. "After 1", P < 0.025
vs. "After 2"). The value for CORT-treated animals was also
significantly lower than that for SAL-treated controls (P <
0.01). There was no difference in food efficiency between the
two groups at any other time interval.
Pituitary cell response to GHRH
The results of the in vitro perifusion studies are illustrated in
Figure 4. The 45-day-old SAL group showed the lowest re-
sponse to GHRH. CORT treatment caused a highly significant
increase (P < 0.0001) when compared to saline control. By 73
days of age there was no difference between the CORT and
SAL groups, and neither group was different from the 45-day-
old CORT group. A significant age difference existed between
the saline-treated groups. The 73d-SAL group was significantly
increased (P < 0.0002) when compared to the 45d-SAL animals.
Analyses of the concentration-response curves (Table I)
showed that the pattern of GH release was linear in all four
groups (P < 0.0001 for each) with respect to the increased
amount of hormone secreted in response to the logarithmic
progression of GHRH concentrations.
Basal GH release and the overall mean response to GHRH
are shown in Table 2. The enhancement of GH release by
CORT was reaffirmed by the higher basal secretory rate and the
greater overall GHRH response in the 45d-CORT group com-
pared to the 45d-SAL controls (P < 0.01). The age-related
increase in GRRH responsiveness was again shown by the
larger release of GH in the 73d-SAL animals compared to the
45d-SAL group.
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Fig. 4. In vitro growth hormone (GH) response of dispersed pituitary
cells to nine (9) concentrations of GH-releasing hormone (GH-RH),
ranging from 0.01 to 100 nanomolar (nM) Gil secretion is expressed in
terms of Gil secretory rate in nanograms per minute per 10 million cells
(ng/min/107 cells), and all values are means SEM. Cortisone treatment
markedly increased (P < 0,0001) the Gil response to GH-RH in
45-day-old rats () compared to saline-treated controls (LII). Seventy-
three-day-old animals (73d-Cort , and 73d-Sal ) were not signifi-
cantly different, showing the transient nature of the cortisone induced
augmentation of in vitro GH release. Characterizations of the concen-
tration-response relationships, and basal and overall GH-RH-stimu-
lated Gil secretion are shown in Tables 1 and 2, respectively.
Discussion
Mosier et al [19, 20] showed that cortisone treatment caused
a retardation of growth in young rats, and that growth after
cortisOne treatment was parallel to that of normal animals, and
did not catch up. Our data on the gain in body weight (Fig. 1)
confirmed these findings. We extended these observations to
examine food efficiency and in vitro GH secretory capacity to
further investigate the mechanisms of growth retardation during
glucocorticoid therapy.
The relationship of nutritional changes to cortisone-induced
growth failure was shown by the fact that food efficiency was
significantly decreased during the period of treatment. Average
food intake, based on the amount of food consumed per 100 g of
body weight, showed a significant increase. This difference in
average food intake, however, occurred during the period
following drug administration and was not related to any
increase in weight gain. The cortisone-treated animals grew at
the same rate as controls, and consumed the same amount of
food. They weighed less as a result of cortisone treatment, but
converted food to body weight as efficiently as control animals.
In this regard, the inhibition of growth by glucocorticoids might
be specifically related to changes in food metabolism, and not to
intake.
Cortisone also induced significant changes in the GH secre-
tory capacity of dispersed pituitary cells in vitro. The basal
secretory rate, the concentration-response relationship with
GHRH, and the overall response of GH secretion to GHRH
were all augmented by cortisone administration. The results
also showed that the GH secretory capacity of young rats
increased with age, since pituitary cells from 73-day-old saline-
treated animals secreted significantly more GH than the 45-day-
old control group. There was no difference between 73-day-old
cortisone-treated animals and the saline-treated animals of the
same age, showing that the augmentation of GH secretion by
cortisone administered at 45 days of age was a transitory event.
These results compare favorably with previous findings that
Slope
Group
(ag/mm io
cells/nM
GHRH)
intercept(nglmin iü
cells) r2 P
45d-SAL 30.4 2.2 123.1 6.4 0.85 0.0001
45d-CORT 45.7 4.8 207.9 14,2 0.73 0.0001
73d-SAL 57.7 5.5 202.9 16.4 0.76 0.0001
73d-CORT 49.8 5.1 191.0 15.2 0.74 0.0001
GHRH-
Group Basal stimulated
45d-SAL 17.6 0.6 122.4 l6,3a
45d-CORT 28.0 O,8l 206.8 26.5k'
73d-SAL 32.7 10b 201.6 328b
73d-CORT 29.7 14b 189.8 28.7"
glucocorticoids induce an increase in pituitary cell GH secre-
tory capacity [21], and that this augmentation follows a signif-
icant increase in GH messenger RNA (mRNA) production and
GH synthesis 122, 23].
The facilitation of GH secretion by pituitary cells in vitro
stands in marked contrast to the inhibition of body growth by
cortisone. Likewise, it contrasts with many in vivo studies in
humans and intact laboratory animals. With the exception of
one study showing the inhibition GHRH-stimulated GH release
by hypoadrenalism with reversal after glucocorticoid replace-
ment therapy [24], the concensus of findings is that glucocorti-
coids exert a significant inhibitory effect on GH release in
humans [8—10, 12, 25]. Likewise, the most recent in vivo results
of Wehrenberg et al [131 show that the same inhibition of GH
secretion occurs in experimental animals treated with dexameth-
asone. These data update previous findings in pentobarbital-
anesthetized rats [261. The former studies [131 suggest that the
mechanism of inhibition might be by the induction of hypo-
thalamic somatostatin secretion by glucocorticoids, since dexa-
methasone inhibition was overriden by the administration of
antibodies to somatostatin.
Although the dose of cortisone used in this study conforms to
that described in the classical studies of Mosier et al [6, 19, 20],
it is still relatively high compared to therapeutic doses in
humans. No glucosuria or signs of infection were observed in
the rats in this study, nor were there potential complications of
high dose steroids reported in the studies by Mosier et al [6, 19,
20]. It should also be recognized that contrary to humans, there
is no catch-up growth in rats after discontinuation of steroid
administration. While this may be a function of dosage, other
major differences in the growth pattern in children clinically
iE
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Table 1. Concentration-response relationships between GHRH and
Gil release for continuously perifused pituitary cells
0.01 0.03 0.1 0.3 1.0 3.0 10 30 100 45d and 73d = 45- and 73-day-old rats, respectively. SAL and CORT
= saline and cortisone treatment, respectively. Values for slope and
intercept are expressed as mean SEM, and P values reflect the
presence of linear concentration-response relationships.
Table 2. Basal and overall mean GHRH-stimulated GH secretory
rates by perifused pituitary cells
All values are expressed as mean (±sEM) secretory rates (ng per
min/107 cells). Treatment groups are the same as in Table I. Secretory
rates within columns identified by different superscripts differ signifi-
cantly (P < 0.01).
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treated with steroids must be appreciated. Steroids have nu-
merous effects besides those on growth hormone, which may
contribute to growth delay to different degrees between humans
and rats, including effects on growth-plate chondrocytes, pro-
tein-energy metabolism, and a host of growth factors.
While it is possible that increased hypothalamic somatostatin
secretion might be involved in the inhibition of growth, other
studies have shown that glucocorticoids also exert potent
inhibitory effects on insulin-like growth factor-i (IGF-i) mRNA
production in bone [7] and on the GH-induced increase in IGF- 1
mRNA in liver and bone [27]. It is also known that the
proteolysis induced by glucocorticoids [28] can be reversed by
GH treatment [29]. These important clinical results further
implicate changes in GH secretion in the inhibition of growth by
glucocorticoids. In this regard, it is likely that glucocorticoids
inhibit growth at several levels ranging from brain secretion of
somatostatin, to the efficiency of food utilization and protein
synthesis, to the ultimate production of IGF-i in the peripheral
target tissues. Paradoxically, it is also apparent that glucocor-
ticoids facilitate the production of GH in pituitary cells, and
augment their responsiveness to GH-releasing stimuli.
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